{"id":61654,"date":"2025-07-29T10:03:31","date_gmt":"2025-07-29T08:03:31","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/"},"modified":"2025-07-29T10:03:31","modified_gmt":"2025-07-29T08:03:31","slug":"virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/","title":{"rendered":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers"},"content":{"rendered":"
\n

\nAvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell\u2019s deep expertise and track record.<\/i><\/p>\n

LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (\u201cViroCell\u201d), a specialist viral vector Contract Development and Manufacturing Organisation (\u201cCDMO\u201d) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration with and the successful delivery of a novel retroviral vector to AvenCell Therapeutics, Inc. (\u201cAvenCell\u201d), a leading clinical-stage cell therapy company focused on advancing allogeneic switchable CAR-T cell therapies. This first retroviral vector will be used to manufacture AVC-203, an investigational CD19\/CD20 dual-targeted cell therapy for the treatment of B cell malignancies and autoimmune diseases.<\/p>\n

<\/a>
<\/a><\/p>\n

\nAvenCell\u2019s AV203 is its second investigational cell therapy using its differentiated allogeneic engineering to provide an \u201coff-the-shelf\u201d product engineered to overcome graft-versus-host disease as well as graft rejection by host T and Natural Killer (\u201cNK\u201d) cells. AVC-203 is designed to achieve superior efficacy compared to currently-approved CAR-Ts while enabling immediate treatment and greater patient access at much lower cost and complexity. The further inclusion of AvenCell\u2019s RevCAR\u2122 receptor in AVC203 allows for additional antigen targeting (with \u201coff\/on\u201d capability in vivo) beyond CD19 and CD20.<\/p>\n

\nAvenCell selected ViroCell as its partner to manufacture the retroviral vector for this program based on the CDMO\u2019s expertise and track record in delivering high yield vectors at speed. Incorporating a cell line acquired by AvenCell into the GMP manufacturing process, ViroCell successfully delivered a high yield vector while meeting AvenCell\u2019s accelerated timeline. This program evidences ViroCell\u2019s ability to deliver a bespoke, complex manufacturing process in the allogeneic CAR-T cell therapy space, ultimately, enabling AvenCell\u2019s timelines for clinical entry. AvenCell\u2019s AVC-203 is expected to enter a first-in-human phase I study in patients with relapsed\/refractory B cell lymphoma in H2\/2025.<\/p>\n

\nJohn W. Hadden II, CEO of ViroCell, commented: <\/b>\u201cWe are thrilled to partner with AvenCell and support their innovative allogeneic CAR-T therapy platform. I am proud of Team ViroCell\u2019s accomplishments on the successful end-to-end delivery of this retroviral vector and accelerating a novel therapy into clinical development in an area of high unmet need. We look forward to continuing our work with AvenCell on their exciting platform.\u201d<\/i><\/p>\n

\nAndrew Schiermeier, Ph.D., CEO, AvenCell, added: <\/b>\u201cWe are delighted with ViroCell\u2019s performance in process development and GMP manufacture of this complex retroviral vector. We selected ViroCell to support our platform because we knew that they could execute reliably in areas where other CDMOs can\u2019t. The delivery of this retroviral vector for AVC-203 is proof that our trust in ViroCell was well placed.\u201d<\/i><\/p>\n

\nNotes to editor:<\/b><\/p>\n

\nViroCell<\/b><\/p>\n

\nViroCell Biologics is an innovation-driven Contract Development and Manufacturing Organization (\u201cCDMO\u201d) focused exclusively on the design, de-risking, and GMP manufacture of viral vectors for clinical trials. Built around one of the most prolific academic viral vector manufacturing teams, ViroCell was created to address the global demand for precisely engineered viral vectors. The team leverages its deep track record to help clients to de-risk and accelerate novel cell and gene therapies into and through clinical development, with a mission of being the partner of choice for corporate and academic innovators. Focused initially on manufacturing lentiviral and retroviral vectors, ViroCell enables clients to start clinical trials on a scalable platform, delivering value by reducing costs, time and regulatory risk.<\/p>\n

\nwww.virocell.com<\/a><\/p>\n

\nAvenCell Therapeutics<\/b><\/p>\n

\nAvenCell derives its name from the French word \u201cavenir\u201d to reflect the aim to be the FUTURE of cell therapy. AvenCell is building a truly transformative cell therapy company that targets difficult-to-treat cancers, with its lead programs focusing on acute myeloid leukemia (AML) and additional programs targeting other hematological malignancies. AvenCell was formed with the goal to create truly allogeneic cells that persist as long or longer than autologous therapies and develop a universal and switchable construct that allows complete control and target redirection of T cells after they are infused into a patient. Integration of these two platforms allows for complete separation of the manufacturing of cells from ultimate patient and cancer target, thus providing significant scalability potential at orders of magnitude more efficient than current approaches.<\/p>\n

\nAvenCell Therapeutics, Inc. was launched in 2021 by Blackstone Life Sciences, Cellex Cell Professionals, and Intellia Therapeutics. AvenCell is headquartered in Watertown, Massachusetts with additional R&D and manufacturing operations in Dresden, Germany.<\/p>\n

\nwww.avencell.com<\/a><\/p>\n

Contacts<\/b> <\/p>\n

\nFor more information, please contact:<\/b>
ViroCell<\/b>
John W. Hadden II, CEO
\n
info@virocell.com<\/a><\/p>\n

\nFor media enquiries, please contact:<\/b>
ViroCell \u2013<\/b>
FTI Consulting<\/b>
Simon Conway \/ Tim Stamper
\n
ViroCell@fticonsulting.com<\/a>
+44 (0)20 3727 1000<\/p>\n

\nAvenCell \u2013<\/b>
H Advisors<\/b>
Emma Prenn-Vasilakis
\n
emma.prenn-vasilakis@h-advisors.global<\/a>
+1 (917) 763-6685<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell\u2019s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (\u201cViroCell\u201d), a specialist viral vector Contract Development and Manufacturing Organisation (\u201cCDMO\u201d) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-61654","6":"format-standard","7":"category-industry"},"yoast_head":"\nViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell\u2019s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (\u201cViroCell\u201d), a specialist viral vector Contract Development and Manufacturing Organisation (\u201cCDMO\u201d) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-29T08:03:31+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers\",\"datePublished\":\"2025-07-29T08:03:31+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/\"},\"wordCount\":790,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728879540\\\/en\\\/2536267\\\/22\\\/ViroCell%2BBiologics%2BLogo_1030x420.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/\",\"name\":\"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728879540\\\/en\\\/2536267\\\/22\\\/ViroCell%2BBiologics%2BLogo_1030x420.jpg\",\"datePublished\":\"2025-07-29T08:03:31+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728879540\\\/en\\\/2536267\\\/22\\\/ViroCell%2BBiologics%2BLogo_1030x420.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20250728879540\\\/en\\\/2536267\\\/22\\\/ViroCell%2BBiologics%2BLogo_1030x420.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/","og_locale":"en_US","og_type":"article","og_title":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend","og_description":"AvenCell selected ViroCell for retroviral vector CDMO services to drive its pipeline of innovative allogeneic CAR T-cell therapies, based on ViroCell\u2019s deep expertise and track record. LONDON & NEW YORK–(BUSINESS WIRE)–ViroCell Biologics (\u201cViroCell\u201d), a specialist viral vector Contract Development and Manufacturing Organisation (\u201cCDMO\u201d) for cell and gene therapy (CGT) clinical trials, announces a manufacturing collaboration ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/","og_site_name":"Pharma Trend","article_published_time":"2025-07-29T08:03:31+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers","datePublished":"2025-07-29T08:03:31+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/"},"wordCount":790,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/","url":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/","name":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg","datePublished":"2025-07-29T08:03:31+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20250728879540\/en\/2536267\/22\/ViroCell%2BBiologics%2BLogo_1030x420.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/virocell-biologics-and-avencell-therapeutics-announce-retroviral-vector-manufacturing-collaboration-to-accelerate-development-of-novel-allogeneic-car-t-therapies-for-blood-cancers\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ViroCell Biologics and AvenCell Therapeutics Announce Retroviral Vector Manufacturing Collaboration to Accelerate Development of Novel Allogeneic CAR-T Therapies for Blood Cancers"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61654","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=61654"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/61654\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=61654"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=61654"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=61654"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}